Company Overview
Snapshot
Founded in February 2023 by Estee Rosen and Gadi Klarsfeld, Hopec Pharma operates with 1–10 employees. The company has raised $4 million across two funding rounds. In October 2025, Hopec Pharma was awarded a grant from the Israel Innovation Authority, marking a significant milestone in its development.
Business overview
Hopec Pharma is dedicated to transforming the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) through its innovative non-intravesical immunotherapy, HOPEC (UPEC-FimON). This genetically modified Uropathogenic E. coli is designed to trigger a targeted immune response, aiming for higher efficacy and fewer side effects compared to existing treatments. The company operates within the Health Tech & Life Sciences sector, specifically focusing on drug development, clinical trials, and targeted cancer therapy within the biopharmaceutical and biotechnology industries, serving patients in markets such as North America, Western Europe, and China.
Log in to access full profile ›Company Intelligence Q&A
- When was Hopec Pharma founded and by whom?
- Hopec Pharma was founded in February 2023 by Estee Rosen and Gadi Klarsfeld.
- What is Hopec Pharma's core technology?
- Hopec Pharma's core technology is HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy that uses genetically modified Uropathogenic E. coli to trigger a targeted immune response for treating Non-Muscle Invasive Bladder Cancer.
- What significant clinical milestones did Hopec Pharma achieve in 2025?
- In 2025, Hopec Pharma produced its first GMP clinical batch (DOR-100), received Helsinki approval in July for Phase 1/a+b trials, signed clinical agreements with Hadassah and Sheba Medical Centers, and launched clinical trials in September.
- Has Hopec Pharma received any grants?
- Yes, in October 2025, Hopec Pharma was awarded a grant from the Israel Innovation Authority.
- What is the total capital raised by Hopec Pharma?
- Hopec Pharma has raised a total of $4 million across two funding rounds.